Inflammatory myopathies (IM) are a group of severe autoimmune diseases, sharing some similarities, whose cause is unknown and treatment is empirical. While C-protein-induced myositis (CIM), the most ...

Objectives Interstitial lung disease associated with rheumatoid arthritis (RA-ILD) is linked to high mortality. Currently, effective screening tools are lacking. We assessed the role of symptoms and ...

Correction: comparison of active tuberculosis occurrence associated with janus kinase inhibitors and biological DMARDs in rheumatoid arthritis ...

It is known that 25%–30% of individuals with cutaneous psoriasis (PsC) will develop psoriatic arthritis (PsA). To date, the reasons for the development of PsA in individuals with PsC have not been ...

Background Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following inadequate response to ...

Objectives To demonstrate efficacy equivalence of CT-P47 and EU-approved reference tocilizumab (r-TCZ) in patients with rheumatoid arthritis (RA).

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of diseases characterised by systemic involvement of small-to-medium vessels with necrotising inflammation that, by ...

Letter to the editor regarding non validated patient and radiofrequency technique for facet pain: re: Truong K. et al.

Objectives To assess the safety and efficacy of upadacitinib versus adalimumab from SELECT-COMPARE over 5 years.Methods Patients with rheumatoid arthritis and inadequate response to methotrexate were ...

Methods This prognostic study analysed patients with PM/DM-ILD admitted to Nanjing Drum Hospital from 2016 to 2021. The primary outcome was mortality within 1 year. We used a least absolute shrinkage ...

What this study adds By studying a large longitudinal cohort of people with untreated early RA followed up for up to 48 weeks, we showed that obesity at diagnosis was a risk factor for poor response ...

Objective This post hoc analysis of the FINCH 1–3 ( NCT02889796, NCT02873936 and NCT02886728) studies assessed specific effects of filgotinib on pain control and their relationship with other aspects ...